LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 439

Search options

  1. Article ; Online: Irradiation à faible dose des affections non cancéreuses : avons-nous jeté le bébé avec l’eau du bain ?

    Cosset, J-M / Deutsch, E

    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique

    2021  Volume 25, Issue 3, Page(s) 279–282

    Abstract: The irradiation of non-malignant diseases, essentially for anti-inflammatory purpose, have been largely proposed and performed worldwide until the 1970-80s. At that time, the better assessment of the radio-induced malignancies, essentially in children ... ...

    Title translation Low-dose irradiation of non-malignant diseases: Did we throw the baby out with the bathwater?
    Abstract The irradiation of non-malignant diseases, essentially for anti-inflammatory purpose, have been largely proposed and performed worldwide until the 1970-80s. At that time, the better assessment of the radio-induced malignancies, essentially in children and young patients, as well as the efficacy of the new anti-inflammatory drugs (steroids and non-steroids), led to the almost disappearance of those techniques, at least in France. In contrast, our German colleagues are still going on treating about 50,000 patients per year for non-malignant (more or less severe) diseases. After a short historical overview, the present article suggests that we were possibly going too far in the rejection of those low-dose irradiations for benign lesions. The recent emergence of new preclinical data, the better understanding of the risk of radio-induced secondary tumours (almost nil in the elderly), and the severity of some situations, such as the cytokine storm of the COVID-19, should probably lead us to reconsider those low - and sometimes very low (less than 1Gy) - irradiations for well-selected indications in the elderly.
    MeSH term(s) Evidence-Based Medicine ; Humans ; Neoplasms, Radiation-Induced ; Radiotherapy/trends ; Radiotherapy Dosage
    Language French
    Publishing date 2021-01-12
    Publishing country France
    Document type Journal Article
    ZDB-ID 1397169-4
    ISSN 1769-6658 ; 1278-3218
    ISSN (online) 1769-6658
    ISSN 1278-3218
    DOI 10.1016/j.canrad.2020.09.002
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Irradiation hypofractionnée du cancer de prostate : quelles connaissances radiobiologiques en 2017 ?

    Cosset, J-M

    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique

    2017  Volume 21, Issue 6-7, Page(s) 447–453

    Abstract: For prostate cancer, hypofractionation has been based since 1999 on radiobiological data, which calculated a very low alpha/beta ratio (1.2 to 1.5Gy). This suggested that a better local control could be obtained, without any toxicity increase. ... ...

    Title translation Hypofractionated irradiation of prostate cancer: What is the radiobiological understanding in 2017?
    Abstract For prostate cancer, hypofractionation has been based since 1999 on radiobiological data, which calculated a very low alpha/beta ratio (1.2 to 1.5Gy). This suggested that a better local control could be obtained, without any toxicity increase. Consequently, two types of hypofractionated schemes were proposed: "moderate" hypofractionation, with fractions of 2.5 to 4Gy, and "extreme" hypofractionation, utilizing stereotactic techniques, with fractions of 7 to 10Gy. For moderate hypofractionation, the linear-quadratic (LQ) model has been used to calculate the equivalent doses of the new protocols. The available trials have often shown a "non-inferiority", but no advantage, while the equivalent doses calculated for the hypofractionated arms were sometimes very superior to the doses of the conventional arms. This finding could suggest either an alpha/beta ratio lower than previously calculated, or a negative impact of other radiobiological parameters, which had not been taken into account. For "extreme" hypofractionation, the use of the LQ model is discussed for high dose fractions. Moreover, a number of radiobiological questions are still pending. The reduced overall irradiation time could be either a positive point (better local control) or a negative one (reduced reoxygenation). The prolonged duration of the fractions could lead to a decrease of efficacy (because allowing for reparation of sublethal lesions). Finally, the impact of the large fractions on the microenvironment and/or immunity remains discussed. The reported series appear to show encouraging short to mid-term results, but the results of randomized trials are still awaited. Today, it seems reasonable to only propose those extreme hypofractionated schemes to well-selected patients, treating small volumes with high-level stereotactic techniques.
    MeSH term(s) Clinical Trials as Topic ; Dose Hypofractionation ; Humans ; Male ; Prostatic Neoplasms/radiotherapy ; Radiobiology
    Language French
    Publishing date 2017-10
    Publishing country France
    Document type Journal Article
    ZDB-ID 1397169-4
    ISSN 1769-6658 ; 1278-3218
    ISSN (online) 1769-6658
    ISSN 1278-3218
    DOI 10.1016/j.canrad.2017.06.006
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: L'aube de la radiothérapie, entre coups de génie, drames et controverses.

    Cosset, J-M

    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique

    2016  Volume 20, Issue 6-7, Page(s) 595–600

    Abstract: Radiotherapy is 120 years old. A few months only after the discoveries of Roentgen, Becquerel and Marie and Pierre Curie, a few scientists tried to use the newly discovered rays to treat patients. The question of the name of the first "radiation ... ...

    Title translation The dawn of radiotherapy, between strokes of genius, dramas and controversies.
    Abstract Radiotherapy is 120 years old. A few months only after the discoveries of Roentgen, Becquerel and Marie and Pierre Curie, a few scientists tried to use the newly discovered rays to treat patients. The question of the name of the first "radiation therapist" remains debated. Although often proposed, Emil Grubbé from Chicago seems to have been disqualified. Leopold Freund from Vienna treated a benign cutaneous lesion. Finally, Victor Despeignes from Lyon appears to be the most serious candidate, having treated in 1896 a gastric cancer, and obtaining a very significant tumour regression. The pioneers of radiotherapy paid a heavy tribute to the development of the specialty; a number of them appears on the - most probably incomplete - list of 352 names engraved on the monument dedicated to the "radiation martyrs" in Hamburg. We must keep in mind that it is only within a few years that a handful of brilliant pioneers built the foundations on which radiotherapy could emerge.
    MeSH term(s) History, 19th Century ; History, 20th Century ; History, 21st Century ; Humans ; Radiotherapy/history
    Language French
    Publishing date 2016-10
    Publishing country France
    Document type Historical Article ; Journal Article
    ZDB-ID 1397169-4
    ISSN 1769-6658 ; 1278-3218
    ISSN (online) 1769-6658
    ISSN 1278-3218
    DOI 10.1016/j.canrad.2016.08.123
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Les 30 ans de la SFRO.

    Mazeron, J-J / Mornex, F / Cosset, J-M / Eschwège, F

    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique

    2021  Volume 25, Issue 5, Page(s) 411–418

    Abstract: The French society of oncological radiotherapy (Société française de radiothérapie oncologique, SFRO) was created in 1990. On the occasion of its thirtieth annual congress, in October 2019, a session was devoted to it, with the objective of exposing its ... ...

    Title translation The 30th anniversary of SFRO, the French society of oncological radiotherapy.
    Abstract The French society of oncological radiotherapy (Société française de radiothérapie oncologique, SFRO) was created in 1990. On the occasion of its thirtieth annual congress, in October 2019, a session was devoted to it, with the objective of exposing its functioning, its actions and its productions during these three decades during which radiotherapy and oncology have undergone unprecedented transformations. We propose in this article to outline the content of this session.
    MeSH term(s) Anniversaries and Special Events ; Congresses as Topic/history ; France ; History, 20th Century ; History, 21st Century ; Humans ; Practice Guidelines as Topic ; Radiation Oncology ; Societies, Medical/history
    Language French
    Publishing date 2021-04-16
    Publishing country France
    Document type Historical Article ; Journal Article
    ZDB-ID 1397169-4
    ISSN 1769-6658 ; 1278-3218
    ISSN (online) 1769-6658
    ISSN 1278-3218
    DOI 10.1016/j.canrad.2021.03.003
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Book: Les tumeurs urologiques

    Cosset, Jean-Marc

    (Bulletin du cancer : FMC ; 1)

    1998  

    Author's details avec la participation de J.-M. Cosset
    Series title Bulletin du cancer : FMC ; 1
    Bulletin du cancer
    Bulletin du cancer ; FMC
    Collection Bulletin du cancer
    Bulletin du cancer ; FMC
    Language French
    Size 50 S.
    Publisher Elsevier
    Publishing place Paris
    Publishing country France
    Document type Book
    HBZ-ID HT009214115
    Database Catalogue ZB MED Medicine, Health

    Kategorien

  6. Article ; Online: Prevention of radiation-induced cancers.

    Chargari, C / Giraud, P / Lacornerie, T / Cosset, J-M

    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique

    2021  Volume 26, Issue 1-2, Page(s) 92–95

    Abstract: The issue of radiation-induced cancers must be taken into consideration during therapeutic irradiations. Risk factors for radiation-induced cancer include: the age of the patients, the volumes irradiated, the presence of risk cofactors and the exposure ... ...

    Abstract The issue of radiation-induced cancers must be taken into consideration during therapeutic irradiations. Risk factors for radiation-induced cancer include: the age of the patients, the volumes irradiated, the presence of risk cofactors and the exposure of critical organs. Those should be part of the therapeutic decision, in terms of indication, as well as choice of the radiotherapy technique (including repositioning systems). We present the update of the recommendations of the French society for radiation oncology on the modalities for preventing radiation-induced cancers.
    MeSH term(s) Age Factors ; Humans ; Neoplasms, Radiation-Induced/prevention & control ; Organs at Risk/radiation effects ; Radiotherapy, Intensity-Modulated/adverse effects ; Radiotherapy, Intensity-Modulated/methods ; Risk Factors
    Language English
    Publishing date 2021-12-22
    Publishing country France
    Document type Journal Article ; Practice Guideline
    ZDB-ID 1397169-4
    ISSN 1769-6658 ; 1278-3218
    ISSN (online) 1769-6658
    ISSN 1278-3218
    DOI 10.1016/j.canrad.2021.09.005
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Curiethérapie prostatique de rattrapage : solution pour les rechutes localisées après irradiation ?

    Cosset, J-M / Créhange, G

    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique

    2017  

    Abstract: Salvage brachytherapy after a first prostate radiation therapy is an emerging technique, which has to be considered in the therapeutic armamentarium in the clinically challenging context of patients with isolated local failure from prostate cancer who ... ...

    Title translation Salvage prostate brachytherapy: A solution for local failures after a primary radiation therapy?
    Abstract Salvage brachytherapy after a first prostate radiation therapy is an emerging technique, which has to be considered in the therapeutic armamentarium in the clinically challenging context of patients with isolated local failure from prostate cancer who may still be considered for cure. These occult failures are more and more frequently diagnosed at an early stage, thanks to targeted biopsies and advances in imaging modalities, such as multiparametric MRI and PET-CT. Salvage brachytherapy benefits from the implantation accuracy of brachytherapy procedures using 3D dosimetry and has resulted in more than 50% tumour control rates with long-term. Incontinence rates are always below those of other salvage treatments such as radical prostatectomy, HIFU or cryotherapy. Today, a consensus has been reached to better define good candidates for salvage brachytherapy with respect to disease characteristics at baseline and at failure. No consensus has been clearly defined yet regarding the choice of the technique (low or high dose rate), the total dose to be delivered, or the volume to be implanted (whole gland or focal). While we await robust data from recently completed phase II studies and given the heterogeneous results in the literature, this technique (although already included in the last 2016 NCCN guidelines) remains to be precisely evaluated, optimally within the frame of controlled trials.
    Language French
    Publishing date 2017-11-06
    Publishing country France
    Document type English Abstract ; Journal Article
    ZDB-ID 1397169-4
    ISSN 1769-6658 ; 1278-3218
    ISSN (online) 1769-6658
    ISSN 1278-3218
    DOI 10.1016/j.canrad.2017.04.009
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Quel rapport alpha/bêta pour le cancer prostatique en 2019 ?

    Cosset, J-M / Chargari, C / Créhange, G

    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique

    2019  Volume 23, Issue 4, Page(s) 342–345

    Abstract: In 1999, Brenner and Hall reported for prostate cancer a very low alpha/beta ratio (1.5Gy). In the following years, this value has been confirmed by a large series of papers, so that this very low alpha/beta ratio became a "dogma", on which a large ... ...

    Title translation Which alpha/beta ratio for prostate cancer in 2019?
    Abstract In 1999, Brenner and Hall reported for prostate cancer a very low alpha/beta ratio (1.5Gy). In the following years, this value has been confirmed by a large series of papers, so that this very low alpha/beta ratio became a "dogma", on which a large number of hypofractionated schemes were being built. This was logical, since this very low value strongly suggested a beneficial advantage of hypofractionation for prostate cancer. However, more recently, several questions arose; first, a number of authors reported, from the analysis of their own data, values of alpha/beta ratio which were higher than the "dogma". Secondly, the three modern "superiority trials", aiming at demonstrating the advantages of hypofractionated schemes, actually failed to show such a superiority, in spite of high equivalent doses (calculated with an alpha/beta of 1.5Gy), reaching up to 84 - 90Gy. In 2018, three review papers/metanalyses shed a new light on what could be the value of the alpha/beta ratio for prostate cancer. In particular, those studies took into account a "time factor" (for repopulation), a parameter which had been either forgotten or underestimated before. In those three studies, the alpha/beta ratio was ranging from 2.7Gy to 4.9Gy. Those data do confirm the sensitivity to the fraction dose variation of prostate cancer, but this sensitivity could be lower than suggested by an alpha/beta ratio of 1.5Gy.
    MeSH term(s) Dose Fractionation, Radiation ; Humans ; Male ; Prostatic Neoplasms/radiotherapy
    Language French
    Publishing date 2019-05-20
    Publishing country France
    Document type Journal Article ; Review
    ZDB-ID 1397169-4
    ISSN 1769-6658 ; 1278-3218
    ISSN (online) 1769-6658
    ISSN 1278-3218
    DOI 10.1016/j.canrad.2019.01.004
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Réirradiations : quels critères décisionnels ?

    Cosset, J-M / Chargari, C / Créhange, G

    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique

    2019  Volume 23, Issue 6-7, Page(s) 526–530

    Abstract: The decision to reirradiate a volume which had been previously irradiated remains in 2019 one of the most difficult challenge for a radiation oncologist. Such a decision has to be based on a number of clinical and technological criteria, and the ... ...

    Title translation Reirradiations: Which decision-making criteria?
    Abstract The decision to reirradiate a volume which had been previously irradiated remains in 2019 one of the most difficult challenge for a radiation oncologist. Such a decision has to be based on a number of clinical and technological criteria, and the radiation oncologist will have to answer three main questions: i) can the patient clinically tolerate a second irradiation in the same previously irradiated area? While waiting for fully reliable individual tests of radiosensitivity, one has to take into account the tolerance of the first irradiation, as well as the comorbidities and/or habits which could impact the patient intrinsic radiosensitivity; ii) do the technical data of the first radiotherapy allow a re-irradiation? Unfortunately, and essentially when the discussion of re-irradiating the patient occurs many years (or even decades) after the first treatment, those precise technical data can be missing; iii) which technique should be used for the re-irradiation? In such a specific situation, the patient should be offered the more precise modern technology: stereotactic radiotherapy, protons, brachytherapy (low-, high-, or pulsed-dose rate). The indisputable improvement of the ballistic precision linked to our new technologies should lead to refine and to develop the indications of re-irradiation in the next future.
    MeSH term(s) Brachytherapy/methods ; Clinical Decision-Making ; Humans ; Proton Therapy ; Radiation Tolerance ; Radiotherapy ; Radiotherapy Dosage ; Re-Irradiation/methods ; Time Factors
    Language French
    Publishing date 2019-08-07
    Publishing country France
    Document type Journal Article
    ZDB-ID 1397169-4
    ISSN 1769-6658 ; 1278-3218
    ISSN (online) 1769-6658
    ISSN 1278-3218
    DOI 10.1016/j.canrad.2019.06.007
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Book ; Online: Efficient Magnon Injection and Detection via the Orbital Rashba Edelstein Effect

    Mendoza-Rodarte, J. A. / Cosset-Chéneau, M. / van Wees, B. J. / Guimarães, M. H. D.

    2024  

    Abstract: Orbital currents and accumulation provide a new avenue to boost spintronic effects in nanodevices. Here we use interconversion effects between charge current and orbital angular momentum to demonstrate a dramatic increase in the magnon spin injection and ...

    Abstract Orbital currents and accumulation provide a new avenue to boost spintronic effects in nanodevices. Here we use interconversion effects between charge current and orbital angular momentum to demonstrate a dramatic increase in the magnon spin injection and detection efficiencies in nanodevices consisting of a magnetic insulator contacted by Pt/CuOx electrodes. Moreover, we note distinct variations in efficiency for magnon spin injection and detection, indicating a disparity in the direct and inverse orbital Rashba Edelstein effect efficiencies.
    Keywords Condensed Matter - Mesoscale and Nanoscale Physics ; Condensed Matter - Materials Science
    Publishing date 2024-01-02
    Publishing country us
    Document type Book ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

To top